Form 4: Dexcom Director Transfers Shares to Trust, Receives Restricted Stock Units

Mark G. Foletta, a director at Dexcom Inc., transferred shares to a family trust and received restricted stock units (RSUs) according to a recent SEC filing.

Summary

• On May 8, 2025, Mark G. Foletta, a director of Dexcom Inc., engaged in transactions involving Dexcom's common stock.
• Foletta transferred 2,973 shares from direct ownership to a family trust.
• The same day, Foletta received 5,731 restricted stock units (RSUs).
• These RSUs will vest on the earlier of May 8, 2026, or the date of Dexcom's 2026 Annual Meeting of Stockholders.
• Following these transactions, Foletta directly owns 5,731 shares and indirectly owns 59,371 shares through a trust.

Sentiment

Score: 5

Explanation: The document reflects standard insider transactions, neither particularly positive nor negative.

Future Outlook

The RSUs will vest on the earlier of May 8, 2026, or the date of Dexcom's 2026 Annual Meeting of Stockholders, representing a future increase in Foletta's direct ownership of Dexcom stock.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company.

Related Party Transactions

• The transfer of shares to the Foletta Family Trust constitutes a related party transaction.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal ownership adjustments.

Key Dates

Keywords

Dexcom, Director, Form 4, SEC Filing, Stock Transfer, Restricted Stock Units, RSUs, Beneficial Ownership, Foletta Family Trust